SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
HB 2513, titled the "Oklahoma Mental Health Reform Act of 2025," proposed creating a position requiring an individual with specific qualifications to address the Department of Mental Health and Substance Abuse Services' court-ordered consent decree. The bill specified requirements for this appointee and included an emergency provision. It was scheduled to take effect November 1, 2025, but was pocket-vetoed by the Governor on May 30, 2025, with the veto taking effect June 15, 2025, meaning it never became law. The bill directly affected the Department's compliance with its existing legal agreement but was not enacted.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 2262 requires nursing homes, assisted living facilities, and other care providers marketing specialized dementia care to publicly disclose detailed information about their services. Facilities must submit a standardized form to Oklahoma's State Department of Health, covering staff ratios, care plans, facility design, activities, fees, and family involvement - ensuring transparency for residents and families considering placement. The bill mandates posting this disclosure online and in facilities, with the Department reviewing it during inspections. It directly affects dementia care providers and supports informed decisions by families seeking appropriate care.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
HB 2298 allows qualified Advanced Practice Registered Nurses (APRNs) in Oklahoma - such as nurse practitioners and nurse-midwives - to prescribe medications independently after meeting specific requirements. To qualify, APRNs must complete 6,240 supervised clinical hours, hold a valid license, and carry $1 million in malpractice insurance per incident. The bill also sets rules for APRN advertising (requiring clear disclosure of their role and scope) and defines supervision requirements for those not yet eligible for independent prescribing. It modifies Oklahoma’s Nursing Practice Act, Pharmacy Act, and Controlled Substances Act to implement these changes.
HB 2584 allows physician assistants (PAs) in Oklahoma to prescribe and administer certain controlled substances under the supervision of a licensed physician, as specified in the Oklahoma Pharmacy Act and Physician Assistant Act. The bill clarifies that pharmacists may dispense these prescriptions only when written by a PA licensed in Oklahoma and supervised by an Oklahoma-licensed physician, and it modifies requirements for practice agreements between PAs and their supervising physicians. It also creates a 9-member Physician Assistant Committee with specific membership rules to oversee PA licensure and practice standards. The law directly affects PAs, supervising physicians, and pharmacists who dispense controlled substances. (Summary based on bill text amendments to Sections 353.1a, 519.2, and 519.3 of Oklahoma statutes.)
SB 804 requires Oklahoma assisted living centers to establish an internal quality assurance committee that meets quarterly. The committee must monitor incidents, resident satisfaction, and care quality - especially medication administration - and recommend policies, with membership including a registered nurse, administrator, direct care staff, and pharmacist as needed. The bill also updates existing rules to mandate monthly medication reviews by nurses/pharmacists, standardized resident screening, posting inspection results online, and individualized care plans. These changes directly affect all licensed assisted living centers in Oklahoma, effective November 1, 2025.
Oklahoma's SB 773 regulates pharmacy benefit managers (PBMs) by prohibiting unfair practices that affect independent pharmacies and patients. It requires PBMs to pay independent pharmacies the same reimbursement rate for identical drugs as they pay PBM-owned pharmacies, banning "spread pricing" where PBMs charge plans more than they pay pharmacies. The bill also prohibits PBMs from charging pharmacies fees for claim submission, network enrollment, or claims processing, and restricts retroactive payment reductions except for fraud or audit errors. These changes directly impact PBMs, pharmacies, and health plans operating in Oklahoma, aiming to ensure fairer payment practices. The bill was vetoed by the governor but overridden by the legislature on May 29, 2025.
HB 2048, the "340B Nondiscrimination Act," prohibits health insurers, pharmacy benefits managers (PBMs), and third-party payors from discriminating against healthcare providers participating in the federal 340B drug discount program. It specifically bans lower reimbursement rates for 340B drugs, extra fees or administrative burdens for 340B entities, exclusion from provider networks based on 340B status, and requirements to disclose 340B-specific billing details. The law applies to all 340B entities - such as community health centers and hospitals participating in the federal program - and ensures they receive equal treatment in billing, reimbursement, and network access. Enforcement is handled by the Attorney General, with the Oklahoma Medicaid program excluded from these provisions.
